Company Profile
Indaptus Therapeutics Stock Price, News & Analysis
- Ticker:
- INDP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.25 USD (-6.02%)
Close
Last updated: August 6, 2026
243M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, INDP closed down 6.02% at $1.25. No new same-company headline was identified in the current news window.
Company overview
Systemic Immunotherapy Platform
Indaptus Therapeutics develops systemically administered immunotherapies for cancer and viral disease. Its Decoy platform uses attenuated, inactivated, non-pathogenic Gram-negative bacteria to activate innate and adaptive immunity while seeking to maintain manageable systemic safety.
Decoy Platform Rationale
The platform is based on the hypothesis that a combination of multi-target immune-activation signals can more effectively initiate antitumor and antiviral responses. Its design seeks to reduce intravenous toxicity while preserving broad stimulation of immune-cell populations.
Strategic Review
The company is undergoing leadership changes and a reassessment of R&D priorities, including the Decoy platform’s clinical and regulatory feasibility, resource allocation, and potential partnerships. General strategic evaluation is not treated as a defined asset-level catalyst.
Future catalysts
Indaptus’s catalysts are its immunotherapy platform and any update that shows the decoy-bacteria approach can still advance. The company needs clearer human proof.
Recent news
- 01
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Indaptus Therapeutics
- 02
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Source: Indaptus Therapeutics
- 03
- 04
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Source: Indaptus Therapeutics
- 05
Indaptus Therapeutics Provides Clinical Update
Source: Indaptus Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Indaptus Therapeutics (INDP)?
Indaptus Therapeutics (INDP) most recently closed at 1.25 USD, a -6.02% move versus the previous session.
What is the market cap of Indaptus Therapeutics (INDP)?
Indaptus Therapeutics currently has a market capitalization of 243M USD on BioPharmSignal.
What does Indaptus Therapeutics do?
Systemic Immunotherapy Platform Indaptus Therapeutics develops systemically administered immunotherapies for cancer and viral disease. Its Decoy platform uses attenuated, inactivated, non-pathogenic Gram-negative bacteria to activate innate and adaptive immunity while seeking to maintain manageable systemic safety. Decoy Platform Rationale The platform is...
On which exchange is INDP stock listed?
Indaptus Therapeutics (INDP) is associated with NASDAQ, United States, Biopharma.
What is Systemic?
Systemic Immunotherapy Platform Indaptus Therapeutics develops systemically administered immunotherapies for cancer and viral disease.
Which conditions is Indaptus Therapeutics targeting with Systemic?
Indaptus Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Indaptus Therapeutics describe recent progress with Systemic?
Indaptus’s catalysts are its immunotherapy platform and any update that shows the decoy-bacteria approach can still advance. The company needs clearer human proof.
What is Immunotherapy?
Systemic Immunotherapy Platform Indaptus Therapeutics develops systemically administered immunotherapies for cancer and viral disease.